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Summary  Deﬁbrillator  shocks,  appropriate  or  not,  are  associated  with  signiﬁcant  morbidity,
as they  decrease  quality  of  life,  can  be  involved  in  depression  and  anxiety,  and  are  known  to  be
proarrhythmic.  Most  recent  data  have  even  shown  an  association  between  shocks  and  overall
mortality.  As  opposed  to  other  deﬁbrillator-related  complications,  the  rate  of  inappropriate  and
unnecessary  shocks  can  (and  should)  be  decreased  with  adequate  programming.  This  review
focuses on  the  different  programming  strategies  and  tips  available  to  reduce  the  rate  of  shocks
in primary  prevention  patients  with  left  ventricular  dysfunction  implanted  with  a  deﬁbrillator,
as well  as  some  of  the  manufacturers’  device  speciﬁcities.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.  CCLcopyrightThis  is  an  open  access  article
under the  CC  BY-NC-SA  license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).MOTS  CLÉS
Déﬁbrillateur  ;
Résumé  Les  chocs  délivrés  par  les  déﬁbrillateurs  automatiques  implantables  sont  associés  à
une baisse  de  la  qualité  de  vie  des  patients  implantés  (dépression,  anxiété),  et  peuvent  avoir
un effet  pro-arythmogène.  Les  études  les  plus  récentes  ont  même  montré  un  lien  entre  les
Abbreviations: AF, Atrial ﬁbrillation; ATP, Antitachycardia pacing; bpm, Beats per minute; ICD, Implantable cardioverter-deﬁbrillator;
VEF, Left ventricular ejection fraction; SVT, Supraventricular tachycardia; VF, Ventricular ﬁbrillation; VT, Ventricular tachycardia.
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chocs  électriques  internes  et  la  mortalité  totale.  Contrairement  aux  autres  complications,  la
fréquence de  ces  chocs  peut  (et  doit)  être  diminuée  grâce  à  une  programmation  adaptée.
Cette revue  de  la  littérature  se  focalise  plus  particulièrement  sur  les  stratégies  disponibles
pour réduire  la  fréquence  des  chocs  chez  les  patients  implantés  en  prévention  primaire  pour
une dysfonction  systolique  ventriculaire  gauche,  ainsi  que  sur  les  spéciﬁcités  des  appareils  des
différents constructeurs.
©  2014  Elsevier  Masson  SAS.  Tous  droits  réservés.  CCLcopyrightThis  is  an  open  access  article
under the  CC  BY-NC-SA  license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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to  improve  speciﬁcity,  while  remaining  safe  (high  sensitiv-Background
Implantable  cardioverter-deﬁbrillators  (ICDs)  signiﬁcantly
reduce  all-cause  mortality  in  the  primary  prevention  of
sudden  cardiac  death  in  patients  at  increased  risk,  espe-
cially  those  with  a  reduced  left  ventricular  ejection  fraction
(LVEF).  The  Multicenter  Automatic  Deﬁbrillator  Implantation
Trial  II  (MADIT-II)  ﬁrst  established  a  strong  mortality  bene-
ﬁt  for  the  ICD  in  patients  with  a  LVEF  ≤  30%  and  a  previous
myocardial  infarction  [1].  The  reduction  in  total  mortality
was  31%  in  patients  implanted  with  a  prophylactic  ICD  com-
pared  with  patients  randomized  to  optimal  medical  therapy.
This  effect  was  durable,  with  a  34%  reduction  at  8  years  by
multivariable  analyses;  six  patients  had  to  be  implanted  to
prevent  one  death  [2].  The  Sudden  Cardiac  Death  in  Heart
Failure  Trial  (SCD-HeFT)  conﬁrmed  these  results  in  patients
with  a  LVEF  ≤  35%  and  ischaemic  or  non-ischaemic  cardiomy-
opathy  [3],  ﬁnally  leading  to  Class  I  recommendations  in  the
current  guidelines  [4].
For  the  past  10  years,  as  the  number  of  prophylactic
ICD  implantations  has  drastically  increased,  so  have  all  the
related  complications:  acute  implant-related  complications
in  up  to  5%  of  patients  (especially  pocket  haematoma,
haemothorax,  pneumothorax,  cardiac  tamponade);  an
almost  1%  rate  of  30-day  mortality;  lead  dislodgement;
pocket  infection  and  lead-related  endocarditis;  lead  and
device  failures;  and  inappropriate  or  unnecessary  shocks  [5].
The  rate  of  inappropriate  shocks  during  the  ﬁrst  year
of  ICD  implantation  is  reported  to  be  6—10%,  affecting
11.5—17.4%  of  patients  in  major  trials  [6,7]. Such  shocks
are  usually  classiﬁed  as  supraventricular  tachycardia  (SVT)-
related  or  oversensing-related  inappropriate  discharges.
The  former  are  the  most  frequent,  due  to  the  absence  or
failure  of  device  discrimination  algorithms,  leading  to  the
misdiagnosis  of  the  supraventricular  origin  of  arrhythmia  as
ventricular,  whereas  the  latter  can  be  ICD-related  (QRS,  T-
wave  or  P-wave  oversensing,  inappropriate  programming),
lead-related  (isolation  defect,  fracture,  dislodgement)  or
environmental  (electromagnetic  interference,  myopoten-
tials).
The  prevalence  of  unnecessary  shocks  is  more  difﬁcult  to
quantify,  as  one  cannot  predict  what  would  have  happened  if
a  shock  had  not  been  delivered  to  a  ventricular  arrhythmia.
These  are  mainly  represented  by  shocks  to  non-sustained
ventricular  tachycardias  (VTs),  which  represent  the  major-
ity  of  detected  VTs.  They  may  also  be  ICD-related,  as
antitachycardia  pacing  (ATP)  can  induce  or  accelerate  ven-
tricular  arrhythmias  and  cause  unnecessary  shocks.  Finally,
the  question  of  whether  sustained  asymptomatic  VT  should
be  treated  remains  controversial.
i
p
vIt  is  now  well  established  that  shocks,  appropriate  or  not,
re  associated  with  signiﬁcant  morbidity,  as  they  decrease
uality  of  life,  can  be  involved  in  depression  and  anxiety,
nd  are  known  to  be  proarrhythmic  [8—11].  Most  recent  data
ave  even  shown  an  association  between  shocks  and  overall
ortality  [6,7]. These  data  are  easily  explained:  patients
ith  more  severe  cardiomyopathy  and  a  poorer  prognosis
sually  present  with  a  higher  ventricular  arrhythmia  burden
nd  thus  may  experience  more  appropriate  shocks;  most
nappropriate  shocks  are  related  to  atrial  ﬁbrillation  (AF),
hich  is  one  of  the  main  factors  associated  with  a  poor
utcome  in  patients  with  heart  failure.  Shocks  were  actu-
lly  thought  to  reﬂect  a more  advanced  cardiac  disease.
he  results  of  the  recent  MADIT  trial  to  reduce  inappropri-
te  therapy  (MADIT-RIT)  demonstrated  that  changing  the  ICD
rogramming  to  reduce  the  rate  of  ICD  shocks  might  lead  to
 reduction  in  overall  mortality  of  up  to  55%  [12].  Even  if  the
nderlying  mechanisms  still  remain  unclear,  the  deleterious
ffects  of  shocks  themselves,  which  can  cause  myocardial
amage,  may  explain  these  ﬁndings.  Shocks  can  be  associ-
ted  with  an  increased  adrenergic  response,  inﬂammation
nd  oxidative  stress,  which  eventually  may  lead  to  an  alter-
tion  of  the  patient’s  haemodynamics  [13—15].
As  opposed  to  other  deﬁbrillator-related  complications,
he  rate  of  inappropriate  and  unnecessary  shocks  can  be
ecreased  with  adequate  programming.  This  review  focuses
n  the  different  programming  strategies  available  to  reduce
he  rate  of  shocks  in  primary  prevention  patients  with
educed  LVEF,  implanted  with  an  ICD.
upraventricular tachycardia
iscrimination
iscrimination  is  used  to  deﬁne  the  ability  of  the  algorithms
or  differentiating  non-ventricular-detected  events  from
rue  ventricular  tachyarrhythmias.  The  early  generations  of
CDs  had  only  rate  detection.  Once  the  ventricular  rate  was
etected  above  a  preprogrammed  rate  during  a  minimal  pre-
peciﬁed  duration,  therapies  were  automatically  delivered.
he  sensitivity  (percentage  of  clinical  ventricular  arrhyth-
ias  accurately  diagnosed  as  ventricular  episodes)  was  high,
ut  the  speciﬁcity  (percentage  of  accurately  diagnosed  ven-
ricular  arrhythmias  among  all  ventricular  episodes)  was
ather  low,  with  a  high-rate  of  inappropriate  therapies.  Algo-
ithms  were  then  progressively  implemented  in  the  softwarety);  they  should  be  used  routinely,  but  in  patients  with
ermanent  complete  atrioventricular  block  in  which  rapid
entricular  rates  can  only  have  a  ventricular  origin.
3 N.  Clementy  et  al.
S
T
r
a
t
t
m
t
s
c
d
t
c
t
s
d
d
f
p
v
r
t
m
d
S
a
D
A
t
u
s
•
•
•
s
(
S
I
s
t
t
t
f
e
i
Figure 1. Biotronik SMART detection algorithm for dual-chamber
implantable cardioverter-deﬁbrillators. Atrial (PP intervals) and
ventricular (RR intervals) cycle lengths are ﬁrst compared; the
rhythm is then checked for stability (RR, PP and PR intervals) in the
RR = PP diagnostic branch, and for multiplicity (N:1 atrioventricular
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ICDs  should  not  be  implanted  in  order  to  improve  discrimina-
tion,  but  should  be  implanted  in  patients  without  permanent
AF  and  needing  to  be  paced.
Figure 2. Boston Scientiﬁc Rhythm ID detection algorithm for
dual-chamber implantable cardioverter-deﬁbrillators. Diagnosis of10  
ingle-chamber algorithms
hree  criteria  are  mainly  used:  the  sudden  onset  crite-
ion  is  able  to  discriminate  sinus  tachycardia  from  VT,
s  the  former  usually  displays  a  gradual  rate  increase;
he  stability  criterion  can  discriminate  AF  from  VT,  as
he  former  usually  displays  irregular  RR  intervals;  the
orphology  criterion  is  used  to  discriminate  supraven-
ricular  from  ventricular  arrhythmia  by  comparing  the
imilarity  of  the  ventricular  electrogram  during  tachy-
ardia  with  a  reference  electrogram  template  acquired
uring  a  rhythm  in  which  the  supraventricular  origin  is  cer-
ain.
These  three  main  algorithms  can  usually  be  used  in
ombination  to  improve  discrimination  accuracy.  In  a tiered-
herapy  cardioverter-deﬁbrillator  study,  a  programmed
tability  of  40  ms  (interval  maximum  variation  between
etected  interval  and  any  of  the  three  previous  intervals)
ecreased  detection  of  AF  by  95—99%,  with  a  sensitivity
or  true  VT  episodes  of  100%  [16].  In  the  same  study,  a
rogrammed  sudden  onset  ratio  of  87%  (detected  inter-
al  divided  by  the  mean  of  the  four  preceding  intervals)
ejected  98%  of  sinus  tachycardia  episodes,  while  0.5%  of
rue  VT  episodes  were  misdiagnosed.  A  strategy  of  program-
ing  both  stability  and  onset  criteria  has  proven  effective  in
ecreasing  the  rate  of  inappropriate  therapies  by  >  50%  [17].
ome  manufacturers  have  since  implemented  morphology
lgorithms  (Table  1).
ual-chamber algorithms
ddition  of  an  atrial  lead  allows  analysis  of  the  atrioven-
ricular  relationship  during  arrhythmia.  Each  manufacturer
ses  its  own  approach,  but  the  main  principles  are
imilar:
if  the  ventricular  electrograms  are  more  frequent
than  the  atrial  electrograms  (V  >  A),  which  is  actu-
ally  the  case  in  >  90%  of  VTs,  the  ventricular  origin  is
certain;
if  the  number  of  detected  ventricular  electrograms  equals
those  from  the  atrium  (V  =  A),  the  supraventricular  ori-
gin  is  more  probable,  although  VT  with  a  1:1  retrograde
conduction  cannot  be  ruled  out;
if the  atrial  electrograms  are  more  frequent  (A  >  V),  the
supraventricular  origin  is  also  more  probable,  although
dual-tachycardia  should  also  not  be  ruled  out  (VT  in  a
patient  with  AF,  for  instance).
Single-chamber  algorithms  and  PR  association  analy-
es  are  then  implemented  to  achieve  a  ﬁnal  diagnosis
Figs.  1—5).
ingle or dual-chamber?
f  the  Detect  Supraventricular  Tachycardia  (DETECT  SVT)
tudy  showed  better  speciﬁcity  in  dual-chamber  patients,
he  rate  of  inappropriate  therapies  was  signiﬁcantly  higher
han  in  single-chamber  patients  [18];  this  might  be  related
o  the  prerequisite  of  reliable  atrial  sensing  for  accurate  per-
ormance  of  dual-chamber  algorithms.  Atrial  undersensing,
specially  frequent  when  AF  occurs,  atrial  undercount-
ng  due  to  atrial  blanking  periods,  and  atrial  oversensing
v
r
p
tssociation) in the RR > PP branch. The RR < PP branch is diagnostic
or ventricular tachycardia (VT). SVT: supraventricular tachycardia.
often  due  to  far-ﬁeld  R-wave  sensing),  may  all  impair  dual-
hamber  discrimination  and  lead  to  inappropriate  therapies.
oreover,  it  has  been  demonstrated  that  dual-chamber  ICD
mplantations  are  associated  with  a  50%  increase  in  peri-
perative  adverse  events  and  a  two-fold  increase  in  the
erioperative  mortality  rate  compared  with  single-chamber
DC  implantations  [19].  It  is  now  accepted  that  dual-chamberentricular tachycardia (VT) requires either a higher ventricular
ate (V rate) than atrial rate (A rate) or a non-correlated mor-
hology associated with stable RR intervals. SVT: supraventricular
achycardia; VTC: vector timing and correlation.
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Table  1 Main  discrimination  algorithms  speciﬁc  to  the  latest  generation  of  single-chamber  implantable  cardioverter-deﬁbrillators.
Biotronika Boston  Scientiﬁcb Medtronicc St.  Jude  Medicald Sorin  Groupe
Sudden  onset Fulﬁlled  if  the  average
of  the  last  four  DIs  is
X%  shorter  than  the
average  of  the  previous
DI  (eight  DI  sliding
window)
Nominal:  X  =  20%
Available  with  onset/stability  only
Fulﬁlled  if  the  average  of  the  four
consecutive  DIs  following  sudden
onset  is  X%  shorter  than  the
average  of  the  four  consecutive  DIs
preceding  the  two  intervals  before
sudden  onset
Nominal:  X  =  9%
Fulﬁlled  if  the  average
of  four  DIs  is  <  X%  of  the
average  of  the  four
previous  DIs
Nominal:  X  =  81%
Fulﬁlled  if  the  average  of  the
last  four  DIs  is  >  X%  (adaptive)
or  <  Y  ms  (ﬁxed)  shorter  than
one  of  the  averages  of  four
consecutive  DIs  within  the
last  eight  DIs
Nominal:  X  =  18%;  Y  =  100  ms
Fulﬁlled  if  a  DI  is  >  X%
shorter  than  the
average  of  the  four
previous  DIs
Nominal:  X  =  19%
Stability  Fulﬁlled  if  the
difference  between  a
DI  and  each  of  the
three  previous  DIs
is  <  X  ms
Nominal:  X  =  24  ms
Available  with  onset/stability,  and
with  rhythm  ID  for  redetection  only
Fulﬁlled  if  a  DI  varies  by  >  X  ms
from  the  average  variation  of  the
ﬁve  previous  intervals
Nominal:  X  =  30  ms  (rhythm  ID)  or
20  ms  (onset/stability)
Fulﬁlled  if  the  fourth  DI
is  within  X  ms  of  the
three  preceding  DIs
Nominal:  X  =  40  ms
Fulﬁlled  if  the  difference
between  the  second  longest
and  the  second  shortest
interval  during  a  window  of  X
consecutive  DIs  is  <  Y  ms
Nominal:  Y  =  80  ms;  X  =  eight
Fulﬁlled  if  a  majority
(>  X%)  of  DIs  within  the
last  Y  intervals  vary
by  <  Z  ms
Nominal:  X  =  75%;
Y  =  eight;  Z  =  65  ms
Morphology  None  Available  with  rhythm  ID  for  initial
detection  only
Vector  timing  and  correlation:  SVT
is  indicated  if  three  of  the  last  10
complexes  are  similar  (>  X%)  to
template;  VT  is  indicated  if  eight
of  the  10  last  complexes  are  not
correlated
Nominal:  X  =  94%
Wavelet:  detection  is
suspended  if  three  of
the  last  eight
complexes  are  similar
(>  X%)  to  template;
detection  is  fulﬁlled  if
six  of  the  last  eight
complexes  differ  (<  X%)
from  template
Nominal:  X  =  70%
Far-ﬁeld  morphology
discrimination:  SVT  is
indicated  if  Y  out  of  Z  DIs  are
similar  (>  X%)  to  template
Nominal:  X  =  90%;  Y  =  three
out  of  Z  (=  10  DIs)
None
Others  None  None  None  None  Long  cycle  occurrence:
therapy  is  inhibited  for
24  cycles  if  a  DI  is
longer  than  the
average  of  the  four
previous  DIs  by  >  X  ms
Nominal:  X  =  170  ms
DI: detected interval within a VT therapy zone; SVT: supraventricular tachycardia; VT, ventricular tachycardia; X, Y and Z: programmable values.
a Berlin, Germany.
b Natick, MA, USA.
c Minneapolis, MN, USA.
d St. Paul, MN, USA.
e Milan, Italy.
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Figure 3. Medtronic enhanced PR Logic/Wavelet detection algorithm for dual-chamber implantable cardioverter-deﬁbrillators. Tach-
yarrhythmias are classiﬁed according to prespeciﬁed patterns, according to atrioventricular (AV) relationship, morphology and regularity.
A far-ﬁeld R-wave (FFRW) algorithm is also used to discriminate ventric
sinus tachycardia; SVT: supraventricular tachycardia; V: ventricular; VT:
Speciﬁcities of biventricular devices
Discrimination  during  cardiac  resynchronization  therapy
usually  uses  the  same  dual-chamber  algorithms,  but  in
patients  with  chronic  AF.  As  patients  with  biventricular
devices  are  supposed  to  be  paced  permanently,  a  morphol-
ogy  algorithm  may  appear  less  relevant,  as  a  template  of
Figure 4. St. Jude Medical Discrimination algorithm for dual-
chamber implantable cardioverter-deﬁbrillators. Three decision
branches according to atrioventricular relationship are initially
used; discrimination is then performed using programmable single-
chamber algorithms (morphology, sudden onset and stability). Initial
cavity (chamber onset, atrial [A] or ventricular [V]) helps to dis-
criminate 1:1 atrial tachycardia in the A = V branch. AVA: atrial
ventricular association; MD match: morphology similar to template;
SVT: supraventricular tachycardia; VT: ventricular tachycardia.
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 ventricular tachycardia.
he  spontaneous  QRS  might  not  be  obtained.  In  Boston  Sci-
ntiﬁc  devices,  for  instance,  a  stability/onset  algorithm  is
avoured  over  morphology.
ubcutaneous deﬁbrillator
ameron  Health  (Boston  Scientiﬁc)  has  developed  a  speciﬁc
iscrimination  algorithm  for  the  S-ICD  System,  which  uses,
n  a so-called  ‘‘conditional  zone’’,  three  criteria  for  analysis
f  morphology:
comparison  of  the  QRS  morphology  with  a  memorized
template  (static  morphology);
comparison  of  the  QRS  morphology  with  the  morphology
of  the  previous  complex  (dynamic  morphology);
change  in  QRS  width.
Three  far-ﬁeld  sensing  vectors  are  available  for  the  anal-
sis  of  morphology.  A  sensitivity  for  appropriate  detection
f  ventricular  tachyarrhythmias  of  100%  and  a  speciﬁcity
or  supraventricular  arrhythmias  of  98%  were  shown  in  the
TART  study,  in  which  S-ICD  discrimination  was  even  bet-
er  than  some  conventional  transvenous  systems  [20].  A
tandard  shock  zone  is  also  programmable  with  rate-only
etection.
Discrimination  algorithms  have  become  mandatory  to
educe  the  rate  of  inappropriate  detection  of  supraven-
ricular  arrhythmias  and  their  subsequent  treatment.  The
lgorithms  are  rather  diverse  because  of  proprietary  patents
rom  the  different  manufacturers.  A  precise  understanding
f  these  algorithms  is  useful  to  appropriately  reprogramme
he  device  after  a  therapy  is  delivered.
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Figure 5. Sorin Group PARAD+ detection algorithm for dual-chamber implantable cardioverter-deﬁbrillators. Discrimination is based on
analysis of stability, PR association (N:1 atrioventricular association), long cycle occurrence (VTLC), sudden onset and chamber onset (atrial
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s[A] or ventricular [V]), in this speciﬁc order. AF: atrial ﬁbrillatio
ventricular tachycardia.
Oversensing discrimination
Device-related oversensing
Around  10%  of  inappropriate  therapies  result  from
noise/artefact  and  oversensing  [21].  Speciﬁc  algorithms
have  been  developed  to  avoid  signal-related  oversensing,
and  T-wave  oversensing  has  become  rare  (2%),  although  it
might  still  occur  in  speciﬁc  situations  (electrolyte  abnor-
malities,  drugs)  or  patients  (low  ventricular  electrogram
amplitude,  hypertrophic  cardiomyopathy,  short/long  QT
and  Brugada  syndromes),  usually  causing  ventricular  dou-
ble  counting.  All  latest  generation  ICDs  allow  automatic
adjustment  of  the  sensitivity  threshold  on  the  detected
R-wave  amplitude,  with  smooth  decay  with  time,  usually
preventing  T-wave  detection.  Some  manufacturers,  such  as
Medtronic,  Boston  Scientiﬁc  and  St.  Jude  Medical,  rely  on
algorithms  to  improve  signal  processing  (frequency  anal-
ysis  with  band-pass  ﬁlters)  and  thus  noise-to-signal  ratio
[22,23].  Biotronik  and  St.  Jude  Medical  enable  the  adjust-
ment  of  detection  algorithms  (threshold  start  value  and
decay  delay),  but  these  must  be  used  with  caution  as
they  might  compromise  sensing  of  ventricular  tachyarrhyth-
mias.
Lead-related oversensing
Inappropriate  shocks  on  oversensing  are  mainly  related  to
lead  fracture  (up  to  1.1%  per  year)  [21].  Kleemann  et  al.
reported  a  40%  rate  of  ICD  lead  dysfunction  at  8  years
[24].  These  failures  are  often  lead  material  and  design  spe-
ciﬁc,  such  as  in  the  Medtronic  Fidelis  and  St.  Jude  Medical
Riata  leads.  Some  algorithms  have  been  developed  based
on  signal  processing,  with  analysis  of  both  near-ﬁeld  and
far-ﬁeld  electrograms  (noise  usually  manifests  on  near-
ﬁeld  signals),  avoiding  83.7%  of  inappropriate  shocks  in
a  computer  model  study  [23].  Coupled  with  variation  in
lead  impedance  measurements,  the  Medtronic  algorithm,
for  instance,  automatically  prolongs  detection  duration
and  alerts  the  patient;  this  allowed  a  drastic  reduction
c
s
t
zl: atrial ﬂutter; AT: atrial tachycardia ST: sinus tachycardia; VT:
n  the  rate  of  inappropriate  shocks  in  patients  implanted
peciﬁcally  with  Sprint  Fidelis  leads  [25],  but  may  also  be
seful  with  non-Medtronic  leads  [26]. Detection  of  ven-
ricular  oversensing/noise  events  then  withholds  therapy
elivery,  without  compromising  sensitivity  to  ventricular
rrhythmias.  Combined  with  home  monitoring,  this  allows
apid  and  adequate  management  of  ICD  lead  defects  in
hese  patients  (device  deactivation  and  surgical  revision)
27,28].
ther detection algorithms
edetection
ccurring  after  therapy  delivery,  redetection  determines
hether  an  episode  has  terminated.  Typically,  three  to
ight  intervals  classiﬁed  as  sinus  are  required  to  termi-
ate  the  treatment  sequence.  It  is  important  to  point  out
hat  during  redetection,  the  discrimination  algorithm  uses
ewer  algorithms  (or  sometimes  none)  than  are  necessary
uring  initial  detection,  depending  on  the  manufacturer,
o  avoid  delaying  the  next  therapy.  As  stated  by  Koneru
t  al.,  reducing  the  number  of  redetection  intervals
ight  be  interesting  in  some  patients  with  incessant  VT
pisodes  associated  with  temporary  efﬁcacy  of  ATP,  per-
itting  repetition  of  the  ﬁrst  sequence  without  moving
owards  more  aggressive  therapies  [29].  Conversely,  rede-
ection  duration  may  be  increased  if  VT  termination  by
TP  is  systematically  preceded  by  a  transient  accelera-
ion.
econﬁrmation
hese  algorithms  ensure  whether  an  arrhythmia  has
elf-terminated  after  capacitor  charging.  After  charge
ompletion,  a  window  of  a  few  detected  beats  allows
hock  abortion  whenever  detected  intervals  are  longer
han  the  maximum-programmed  interval  in  the  therapy
one.  Inappropriate  shocks  may  still  be  delivered  if  the
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e14  
herapy  zone  (including  the  monitoring  zone  in  some
evices)  is  programmed  to  a  long  cycle  length  when  a
inus  tachycardia  follows  ventricular  arrhythmia  sponta-
eous  resumption.  A  new  shock  algorithm  from  Medtronic
ddresses  this  concern  by  aborting  therapy  whenever  rede-
ected  intervals  are  ≥  60  ms  longer  than  the  detected  VT
ntervals.
imers
hese  algorithms  (called  Sustained  Rate  Duration,  High-Rate
ime  Out,  SVT  Time  Out  or  Sustained  VT)  induce  therapy
elivery  whenever  an  event  (supraventricular  or  ventricular)
asts  longer  than  a  programmable  duration  value.  There  is  a
onsensus  that  these  algorithms  should  be  turned  to  OFF  to
void  inappropriate  therapies  for  sustained  SVT  events.
ntitachycardia pacing
his  mode  of  therapy  consists  of  an  overdrive  pacing  that
mploys  ventricular  stimulation  at  intervals  that  are  shorter
han  the  tachycardia  cycle  length.  ATP  offers  several  advan-
ages:  it  has  been  proven  to  be  a  painless  but  effective
herapy,  reducing  the  necessity  of  shock  delivery  and  hospi-
alization,  improving  patient  quality  of  life,  and  increasing
attery  longevity.
low ventricular tachycardia
elow  180  bpm,  ATP  has  been  proven  efﬁcient  in  treating  VT
pisodes  [30],  but  therapies  for  low  ventricular  rates  should
ot  be  initially  programmed  in  primary  prevention  patients.
onversely,  adding  a  monitoring  zone  for  slow  VT  may  be
nteresting  to  document  symptomatic  events.
ast ventricular tachycardia
bove  180  bpm,  ATP  has  been  proven  to  efﬁciently  treat
ost  monomorphic  VT  episodes.  Grimm  et  al.  reported  86%
f  episodes  terminated  with  ATP  (mean  VT  rate:  204  bpm)
31].  In  the  PROVE  trial,  ATP  (two  bursts,  eight  stimuli,
8%  of  tachycardia  cycle  length)  terminated  92%  of  VT
pisodes  [32].  The  PITAGORA  (Project  for  the  Investiga-
ion  and  Treatment  of  ventricular  Arrhythmias:  a  General
bservational  Registry  on  Antitachycardia  pacing  efﬁcacy)
CD  trial  randomly  compared  two  ATP  strategies  for  fast
T  episodes  >  187  bpm  (one  sequence  of  88%  coupling  inter-
al,  eight-pulse  burst  versus  one  sequence  of  91%  coupling
nterval,  eight-pulse  ramp)  and  demonstrated  a  75%  efﬁ-
acy  for  burst  versus  54%  for  ramp  [33].  A  15-pulse  ATP
trategy  did  not  show  any  superiority  over  an  eight-pulse
trategy  [34].  More  recently,  Martins  et  al.  showed  that  one
r  two  sequences  of  ATP  terminated  >  98%  of  fast  VT  episodes
average  of  1.1  ATP  sequences),  but  programming  up  to  10
ttempts  (ﬁve  bursts  then  ﬁve  ramps)  remained  safe,  while
voiding  shocks  in  12.4%  of  patients  [35].If  ATP  programming  is  selected,  there  is  enough  evidence
o  suggest  that  at  least  two  sequences  of  ATP  should  be  pro-
rammed,  with  eight  stimuli  bursts  at  88%  of  the  tachycardia
ycle  length.
l
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entricular ﬁbrillation zone
n  the  ventricular  ﬁbrillation  (VF)  zone,  ATP  should  be  pro-
rammed  before  or  during  charging,  when  available,  as  it
as  proven  safe  and  efﬁcient.  Schoels  et  al.  reported  efﬁca-
ies  for  monomorphic  and  polymorphic  VT  episodes  of  77%
nd  44%,  respectively  [36].
hocks
lthough  the  subject  remains  controversial,  current  data
o  not  support  the  systematic  testing  of  the  deﬁbrillation
hreshold  or  safety  margin  [37]. Therefore,  until  further
ata  are  available,  programming  maximum  energy  shocks
outinely  can  be  recommended.  Beyond  better  efﬁcacy,
hey  have  not  been  proven  to  be  more  painful  than  lower
nergy  shocks  and  the  slightly  longer  capacitor  charging
ime  may  allow  arrhythmias  (appropriately  or  inappropri-
tely  detected)  to  self  terminate.
one programming
n  primary  prevention  patients,  two  programming  options
ay  appear  relevant:  single  zone  programming  with  a  VF
one  (discrimination  OFF)  and  a  monitoring-only  zone  below;
ual-zone  programming  with  a  VT  zone  (discrimination  ON)
ith  ATP  followed  by  shocks,  and  a  VF  zone  above.
The  latter  strategy  may  not  necessarily  be  more  efﬁcient
han  programming  for  a  single  (VF)  zone.  Duncan  et  al.,
n  a  retrospective  study,  compared  patients  programmed
or  a  single  VF  zone  (mean  >  193  bpm)  with  patients  pro-
rammed  for  two-zones  (mean  VT  zone  >  171  bpm,  mean  VF
one  >  205  bpm)  [38]. The  two-zone  group  actually  received
ore  appropriate  shocks  than  the  group  with  a  single
F  zone  (22%  and  12%,  respectively).  As  efﬁcient  as  it
an  be,  ATP  is  only  useful  if  a  true  SVT  event  is  not
isdiagnosed  as  VT.  Moreover,  ATP  programming  may  not
lways  prevent  symptoms,  as  it  may  only  delay  the  occur-
ence  of  an  efﬁcient  therapy;  it  may  also  accelerate
on-sustained  VT  and  provoke  unnecessary  ICD  shock.  In
he  study  by  Grimm  et  al.,  this  was  the  case  in  up  to  14%
f  VT  episodes  and  48%  of  patients  [31].  More  recently,
chukro  et  al.  showed  that  8.5%  of  patients  presented  with
ccelerated  ventricular  tachyarrhythmias  within  a  mean
ollow-up  of  >  5  years,  mainly  caused  by  appropriate  ATP,
nd  that  this  was  associated  with  a  higher  mortality  rate
39].
The  same  concerns  can  be  applied  to  inappropriate  ther-
pies.  In  MADIT-II,  the  incidence  of  inappropriate  shocks
as  11.5%  [6]. Similarly,  in  the  Pacing  Fast  VT  Reduces
hock  Therapies  (PainFREE  Rx  II)  trial,  15%  of  primary  pre-
ention  patients  had  inappropriate  therapies,  despite  the
ystematic  use  of  ATP  for  fast  VT  episodes  (>  188  bpm)  [40].
n  the  Detect  Supraventricular  Tachycardia  Study,  inappro-
riate  therapies  remained  very  frequent  and  31%  of  SVT
pisodes  were  inappropriately  detected  [18].  In  a  ‘‘real-
ife’’  prospective  study  of  1544  patients  (mean  follow-up
1  months)  at  least  one  inappropriate  shock  occurred  in  13%
f  ICD  recipients  [41]. Devices  were  programmed  with  a
onitoring  zone  of  150—188  bpm,  a  VT  zone  with  two  bursts
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of  ATP  of  188—210  bpm  and  a  shock-only  zone  above.  Inap-
propriate  shocks  were  related  to  SVT  or  sinus  tachycardia
episodes  in  76%  of  cases  (11.5%  of  patients).  In  the  study  by
Duncan  et  al.,  inappropriate  shocks  were  also  more  frequent
in  the  two-zone  programming  group  (10%  vs  2%)  [38]. There
was  no  SVT-related  inappropriate  shock  in  the  single  VF  zone
group.
Detection duration
Programming  long  detection  intervals  is  effective  in  reduc-
ing  both  appropriate  and  inappropriate  therapies.  The
EMPIRIC  (Comparison  of  Empiric  to  Physician-Tailored  Pro-
gramming  of  Implantable  Cardioverter-Deﬁbrillators)  trial
has  already  shown  that  standardized  programming  with
longer  intervals  (18  of  24)  in  the  VT  zone  is  associated
with  a  signiﬁcant  reduction  in  shocks  of  any  cause  [42].  The
Primary  Prevention  Parameters  Evaluation  (PREPARE)  study
compared  a  long-delay  strategy  (30  of  40  detection  inter-
vals  for  fast  VT  >  182  bpm,  30  of  40  for  VF  zone  >  250  bpm)
with  a  standard  programming  cohort  [43].  After  12  months  of
follow-up,  the  rate  of  appropriate  shocks  in  the  long-delay
group  was  8.5%  (43%  reduction)  and  the  rate  of  inappro-
priate  shocks  was  3.6%  (a  52%  reduction).  The  RELEVANT
(Role  of  long  dEtection  window  programming  in  patients
with  LEft  VentriculAr  dysfunction,  Non-ischemic  eTiology  in
primary  prevention  treated  with  a  biventricular  ICD)  study
used  30  of  40  detection  intervals  in  non-ischaemic  patients,
with  an  84%  reduction  in  inappropriate  shocks  [44].  Inter-
estingly,  >  90%  of  VT  episodes  detected  after  12  intervals
spontaneously  resumed  before  reaching  30  intervals.  Most
VT  episodes  are  non-sustained,  and  if  ATP  is  very  efﬁcient,  it
is  also  probably  useless  for  the  majority  of  episodes  and  may
lead  to  a  signiﬁcant  amount  of  unnecessary  shocks.  Indeed,
an  88%  reduction  in  appropriate  therapies  was  observed
in  the  long-delay  group.  There  was  also  a  trend  towards
reduction  in  appropriate  shocks  in  the  long-delay  group,
although  this  was  not  signiﬁcant.  The  usefulness  of  a  strat-
egy  of  programming  a  30  of  40  intervals  detection  window
was  recently  conﬁrmed  in  the  randomized  ADVANCE  III  trial
[45].
The  MADIT-RIT  trial  randomized  1500  primary  prevention
patients  into  three  groups:
• a standard  ICD  programming  group  (170—199  bpm  VT  zone
with  a  2.5  s delay,  ≥  200  bpm  VF  zone  with  a  1.0  s  delay);
• a  high-rate  cut-off  programming  group  (170—199  bpm
monitoring  zone,  ≥  200  bpm  VF  zone  with  a  2.5  s delay);
• a  prolonged-delay  programming  group  (170—199  bpm  VT1
zone  with  a  60  s  delay,  200—249  bpm  VT2  zone  with  a  12  s
delay,  ≥  250  bpm  VF  zone  with  a  2.5  s  delay)  [12].
After  a  mean  follow-up  of  1.4  years,  the  reduction  in
occurrence  of  ﬁrst  inappropriate  therapy  in  the  long-delay
group  compared  with  in  the  standard  programming  group
was  76%.  The  reduction  in  all-cause  mortality  was  44%.
When  treating  in  the  VT  zone  is  decided  upon,  it  is  safe  to
say  that  detection  duration  should  exceed  30  of  40  intervals
in  Medtronic  devices  before  ATP,  and  eventually  shocks,  are
delivered.  Appropriate  detection  timings  with  the  (very)  dif-
ferent  classiﬁcation  and  binning  algorithms  of  other  major
manufacturers  still  wait  to  be  assessed,  but  detection  should
c
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e  programmed  in  order  to  exceed  10  s  between  tachycardia
nset  and  therapy  delivery  [46,47].  However,  despite  a  dras-
ic  improvement  in  discrimination  algorithms,  SVT  episodes
ay  still  be  inappropriately  detected  and  then  treated  if
ustained.  Thus,  in  the  RELEVANT  study,  around  90%  of  inap-
ropriate  episodes  were  related  to  SVT,  both  in  the  group
rogrammed  with  longer  detection  intervals  and  in  the  con-
rol  group.
etection rate
n  the  SCD-HeFT  trial,  a  single  VF  zone  at  188  bpm  was  pro-
rammed  (18  of  24  beats),  leading  to  a  high  incidence  of
hocks  for  VT  episodes  that  may  have  been  asymptomatic
nd  non-sustained  [7]. Some  of  these  appropriate  shocks
ay  then  have  been  unnecessary  therapies  for  appropriately
etected  episodes.  Indeed,  the  PainFREE  Rx  II  trial  found
hat  approximately  34%  of  the  fast  VT  episodes  terminated
pontaneously  during  capacitor  charging  [40].  Inappropriate
hocks  are  also  very  frequent  with  a  low  rate  single  zone
up  to  17.4%  in  SCD-HeFT),  as  SVT  episodes  are  not  discrim-
nated.
In  a  recent  study,  we  showed  that  high-rate  cut-off  pro-
ramming  (single  VF  zone  >  220  bpm)  appeared  to  be  safe
nd  effective  in  maintaining  a  low  rate  of  inappropriate
hocks  (6.6%  of  patients  at  40  months)  [48].  SVT-related
nappropriate  shocks  were  only  present  in  2.7%  of  the
atients  after  a  mean  follow-up  of  3.5  years.  Most  inap-
ropriate  shocks  were  related  to  oversensing  (58%).  The
aximum  ventricular  rate  during  SVT  should  rarely  exceed
20  bpm,  as  conﬁrmed  by  the  results  of  the  Altitude  Reduces
tudy,  which  showed  a  majority  of  inappropriate  shocks  for
n  event  rate  <  200  bpm  and  a  majority  of  appropriate  shocks
or  an  event  rate  ≥  200  bpm  [49].  The  authors  concluded  that
ncreasing  rate  detection  to  ≥  200  bpm  resulted  in  a  four-
old  reduction  in  overall  shock  risk  of  both  appropriate  and
nappropriate  therapies  and  was  not  associated  with  excess
ortality.
The  MADIT-RIT  trial  conﬁrmed  these  results,  with  a  79%
eduction  in  ﬁrst  inappropriate  therapy  occurrence  and  even
 55%  reduction  in  all-cause  mortality  in  the  high-rate  group
cut-off  at  200  bpm),  without  difference  in  risk  of  syncope
12].
Programming  a  single-therapy  zone  without  discrimina-
ion  (VF  zone)  <  200  bpm  should  not  be  performed  in  primary
revention  patients,  as  this  strategy  is  related  to  a high-rate
f  both  appropriate  and  inappropriate  shocks.
igher or later?
o  direct  comparison  has  been  made  between  high-rate
nd  long-delay  strategies,  as  it  was  not  prespeciﬁed  in  the
ADIT-RIT  study  design  [50]. Both  strategies  are  succinctly
ompared  in  Table  2.
Overall,  if  these  strategies  can  be  used  safely,  as  dis-
ussed  previously,  programming  one  single  VF  zone  should
e  associated  with  a  high-rate  cut-off  (≥  200  bpm),  while
rogramming  therapies  in  the  VT  zone  should  be  associated
ith  rather  long  detection  duration  (≥  10  s)  (Fig.  6).
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Table  2  Pros  and  cons  of  long-delay  versus  high-rate  implantable  cardioverter-deﬁbrillator  programming  strategies  in
primary  prevention  patients.
Long-delay  High-rate
Pros Sustained  VT  episodes  <  RCO  are  appropriately
treated
SVT  episodes  <  RCO  cannot  be  inappropriately
treated
Efﬁcient  and  painless  ATP  can  be  extensively  used  Asymptomatic  VT  episodes  <  RCO  are  not  treated
Monitoring  episodes  <  RCO  allow  adequate
reprogramming  if  necessary
Cons Sustained  SVT  episodes  <  RCO  may  be
inappropriately  treated
Symptomatic  sustained  VT  episodes  <  RCO  are  not
treated
Asymptomatic  VT  episodes  <  RCO  are  treated  VT  episodes  ≥  RCO  are  rapidly  treated  with  shocks
ATP  may  cause  unnecessary  shocks
ATP: antitachycardia pacing; RCO: rate cut-off for VF zone in the high-rate strategy; SVT: supraventricular tachycardia; VT: ventricular
tachycardia.
Figure 6. Examples of programming strategies in primary pre-
vention patients. A. Long-delay programming requires up to three
zones: a monitoring zone, a ventricular tachycardia (VT) zone with
a number of detection intervals (NDI) of 30 or more below 200 beats
per minute (bpm) (≥ 10 s detection time), which might even be
extended up to 60 s as in MADIT-RIT, and a ventricular ﬁbrillation
(VF) zone. Antitachycardia pacing (ATP) should also be prioritized
before shocks below 200 bpm. Over 200 bpm, programming an FVT
zone with ATP up to 250 bpm is also possible. B. High-rate cut-off
programming uses a monitoring zone below 200 bpm, and a shock
zone above. ATP burst should be used before or during charging in
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Table  3  Basic  tips  for  programming  implantable
cardioverter-deﬁbrillators  in  primary  prevention
patients.
Bradycardia  pacing  should  be  minimized  in
non-biventricular  devices  (VVI  mode  at  40  bpm,
algorithms  for  reduction  of  ventricular  pacing)
Dual-chamber  is  not  superior  to  single-chamber
discrimination;  an  atrial  lead  should  be  implanted
only  if  pacing  is  needed
Discrimination  algorithms  should  be  used  below
200  bpm,  but  in  patients  with  complete
atrioventricular  block
Prolonged  detection  time  should  be  used  before
delivering  therapies  below  200  bpm  (typically  >  10  s  or
30  intervals)
ATP  should  precede  shocks  below  250  bpm;  the  slower
the  detection  rate,  the  more  ATP  sequences  should  be
used
Maximum  energy  shocks  should  be  used
A  monitoring  zone  should  be  used,  but  should  not
exceed  200  bpm
Redetection  and  reconﬁrmation  should  be  used;
discrimination  timers  should  be  turned  off
Algorithms  to  negate  oversensing  (noise,  T-wave,  etc.)
should  be  used
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raria  from  Biotronik,  Boston  Scientiﬁc,  Medtronic,  St.  Jude
Medical  and  Sorin  Group.he shock zone.
onclusions
areful  programming  of  ICDs  in  primary  prevention  should
emain  a  major  concern  for  physicians  after  implanta-
ion  (Table  3).  Several  studies  have  recently  raised  the
mportance  of  reducing  both  inappropriate  and  unneces-
ary  therapies,  and  manufacturers  have  made  several  tools
vailable  in  order  to  achieve  this  goal.  The  recent  results
rom  the  MADIT-RIT  trial,  showing  the  effect  of  adequate rATP: antitachycardia pacing; bpm: beats per minute.
rogramming  in  reducing  overall  mortality  in  these  patients,
ave  made  this  programming  phase  even  more  crucial.
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